Literature DB >> 8616557

Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles.

J H Morse1, R J Barst, S Itescu, E R Flaster, G Sinha, Y Zhang, M Fotino.   

Abstract

Primary pulmonary hypertension (PPH) may have an autoimmune basis that is influenced by host immunogenetics. The pathogenesis of primary pulmonary hypertension in human immunodeficiency virus (HIV) infection is unclear. The objective of this study was to determine whether patients with PPH and HIV infection have distinctive immunogenetic profiles. Ten racially mixed HIV-infected patients with PPH were typed for human leukocyte antigen (HLA) class II (DRB1, 3, 4, 5 and DQB1) by DNA-PCR sequence-specific oligonucleotide probes. Results were compared with two control groups: 128 HIV-negative Caucasians and a previously reported group of 97 HIV-positive, racially mixed control subjects. In those with PPH, there was a significantly increased frequency of HLA-DR6 (-DRB1*1301/2 subtypes) and of HLA-DR52 (DRB3*0301 subtype). These findings suggest that HIV-associated PPH reflects a host response to HIV-1 determined by one or more HLA-DR alleles located within the major histocompatibility complex. The same HLA-DR6 subtype found at increased frequency in our patients has previously been associated with the development of a CD8 lymphocytic host response to HIV-1, termed diffuse infiltrative lymphocytosis syndrome (DILS), which resembles autoimmune Sjogren's disease and is associated with prolonged survival. Together, these findings suggest that HIV-positive PPH may represent a clinical outcome that has similarities with that resulting from the immunogenetically determined host response present in DILS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616557     DOI: 10.1164/ajrccm.153.4.8616557

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

1.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Injection drug use as a "second hit" in the pathogenesis of HIV-associated pulmonary hypertension.

Authors:  M Patricia George; Hunter C Champion; Mark T Gladwin; Karen A Norris; Alison Morris
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

Review 3.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

Review 4.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

Review 5.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

Review 6.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

Review 7.  Primary pulmonary hypertension associated with human immunodeficiency virus infection.

Authors:  R Golpe; B Fernandez-Infante; S Fernandez-Rozas
Journal:  Postgrad Med J       Date:  1998-07       Impact factor: 2.401

Review 8.  Human immunodeficiency virus-associated pulmonary arterial hypertension.

Authors:  Christopher F Barnett; Priscilla Y Hsue
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

9.  Clinical risk factors for portopulmonary hypertension.

Authors:  Steven M Kawut; Michael J Krowka; James F Trotter; Kari E Roberts; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Robert S Brown; Michael B Fallon
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

10.  Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders.

Authors:  Vichai Atichartakarn; Khanchit Likittanasombat; Suporn Chuncharunee; Pakorn Chandanamattha; Surapon Worapongpaiboon; Pantep Angchaisuksiri; Katcharin Aryurachai
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.